{"transactions":[{"id":943693,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-08T16:05:10.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":142500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 6, 2026 (the \"Grant Date\").  The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service."}],"balance_after":142500,"derivative":{"exercise_price":3.81,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":142500},"source":{"system":"sec-edgar","filing":"0001193125-26-007665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000119312526007665/ownership.xml","form_type":"4"}},{"id":1030034,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-01T17:52:50.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on October 1, 2025 (the \"Grant Date\"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date, and the remainder are scheduled to vest in 36 equal monthly installments through October 1, 2029, subject to the Reporting Person's continued service."}],"balance_after":600000,"derivative":{"exercise_price":1.97,"expiration_date":"2035-09-30","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001193125-25-227099","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000119312525227099/ownership.xml","form_type":"4"}},{"id":1433053,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-08-15T16:15:04.000Z","date":"2024-08-14","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":3.2071,"value":32071.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.17 to $3.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000950170-24-097576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017024097576/ownership.xml","form_type":"4"}},{"id":1441652,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-08-05T16:26:43.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":81065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":81065},"source":{"system":"sec-edgar","filing":"0000950170-24-090813","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017024090813/ownership.xml","form_type":"4"}},{"id":1441651,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T16:26:43.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":124168,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":124168},"source":{"system":"sec-edgar","filing":"0000950170-24-090813","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017024090813/ownership.xml","form_type":"4"}},{"id":1441650,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-05T16:26:43.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16913,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090813","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017024090813/ownership.xml","form_type":"4"}},{"id":1491001,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-05T16:08:16.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":8462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This amendment to Form 4 is being filed solely to correct the price of the derivative security, which was previously reported as being $3.35 due to a scrivener's error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer."}],"balance_after":8462,"derivative":{"exercise_price":3.35,"expiration_date":"2034-05-29","underlying":"Ordinary Shares","underlying_shares":8462},"source":{"system":"sec-edgar","filing":"0000950170-24-069301","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017024069301/ownership.xml","form_type":"4/A","original_submission_date":"2024-06-03"}},{"id":1495847,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-03T10:11:31.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":8462,"price":3.35,"value":28347.7,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer."}],"balance_after":8462,"derivative":{"exercise_price":3.35,"expiration_date":"2034-05-29","underlying":"Ordinary Shares","underlying_shares":8462},"source":{"system":"sec-edgar","filing":"0000950170-24-067702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017024067702/ownership.xml","form_type":"4"}},{"id":1673608,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-23T17:51:54.000Z","date":"2024-01-19","kind":"grant","planned":false,"acquired":true,"shares":81065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":81065,"derivative":{"underlying":"Common Stock","underlying_shares":81065},"source":{"system":"sec-edgar","filing":"0000950170-24-006706","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017024006706/ownership.xml","form_type":"4"}},{"id":1702805,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-12-21T20:12:28.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":false,"shares":30721,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represented the contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":30721},"source":{"system":"sec-edgar","filing":"0000950170-23-072368","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017023072368/ownership.xml","form_type":"4"}},{"id":1702804,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-21T20:12:28.000Z","date":"2023-12-20","kind":"sale","planned":false,"acquired":false,"shares":13808,"price":41.4232,"value":571971.5456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.36 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16913,"source":{"system":"sec-edgar","filing":"0000950170-23-072368","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017023072368/ownership.xml","form_type":"4"}},{"id":1702803,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-21T20:12:28.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":true,"shares":30721,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represented the contingent right to receive one share of the Issuer's common stock."}],"balance_after":30721,"source":{"system":"sec-edgar","filing":"0000950170-23-072368","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017023072368/ownership.xml","form_type":"4"}},{"id":1708229,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-18T16:30:18.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":15021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 14, 2023. This option shall vest over three years in twelve equal quarterly installments on each quarterly anniversary of October 31, 2023, subject to the reporting person's continued service with the Issuer."}],"balance_after":15021,"derivative":{"exercise_price":3.61,"expiration_date":"2033-12-13","underlying":"Ordinary Shares","underlying_shares":15021},"source":{"system":"sec-edgar","filing":"0000950170-23-071107","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017023071107/ownership.xml","form_type":"4"}},{"id":1868310,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-06-05T20:15:04.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":30721,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in four equal annual installments on each of June 1, 2024, June 1, 2025, June 1, 2026 and June 1, 2027, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in four equal annual installments on each of June 1, 2024, June 1, 2025, June 1, 2026 and June 1, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":30721,"derivative":{"underlying":"Common Stock","underlying_shares":30721},"source":{"system":"sec-edgar","filing":"0000950170-23-026503","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017023026503/ownership.xml","form_type":"4"}},{"id":1868309,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T20:15:04.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":124168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on June 1, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":124168,"derivative":{"exercise_price":32.55,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":124168},"source":{"system":"sec-edgar","filing":"0000950170-23-026503","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000095017023026503/ownership.xml","form_type":"4"}},{"id":2076390,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-27T17:14:38.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award."}],"balance_after":123750,"derivative":{"exercise_price":4.74,"exercise_date":"2022-11-14","expiration_date":"2030-07-20","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001415889-22-012991","document":"form4-12272022_101224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000141588922012991/form4-12272022_101224.xml","form_type":"4"}},{"id":2076389,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-27T17:14:38.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":41250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 20, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award."}],"balance_after":41250,"derivative":{"exercise_price":4.74,"exercise_date":"2022-05-20","expiration_date":"2030-07-20","underlying":"Common Stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0001415889-22-012991","document":"form4-12272022_101224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000141588922012991/form4-12272022_101224.xml","form_type":"4"}},{"id":2409252,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Financial Officer"}}],"security":"Common Stock (right to buy)","published_at":"2022-02-08T17:27:40.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":361568,"price":5.32,"value":1923541.76,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant."}],"balance_after":361568,"derivative":{"exercise_price":5.32,"exercise_date":"2023-02-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":361568},"source":{"system":"sec-edgar","filing":"0001179110-22-000926","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000117911022000926/edgar.xml","form_type":"4"}},{"id":2873200,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock (right to buy)","published_at":"2021-02-09T20:11:59.000Z","date":"2021-02-05","kind":"grant","acquired":true,"shares":163798,"price":7.69,"value":1259606.62,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant."}],"balance_after":163798,"derivative":{"exercise_price":7.69,"exercise_date":"2022-02-05","expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":163798},"source":{"system":"sec-edgar","filing":"0001179110-21-001496","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000117911021001496/edgar.xml","form_type":"4"}},{"id":3078393,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":69804,"kind":"person","name":"ALTSCHULLER Susan","position":1,"cik":"0001817988","reported_name":"ALTSCHULLER Susan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock (right to buy)","published_at":"2020-07-22T15:44:29.000Z","date":"2020-07-20","kind":"grant","acquired":true,"shares":300000,"price":4.74,"value":1422000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant."}],"balance_after":300000,"derivative":{"exercise_price":4.74,"exercise_date":"2021-07-20","expiration_date":"2030-07-20","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001179110-20-008407","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817988/000117911020008407/edgar.xml","form_type":"4"}}]}